Brain Trust Accelerator Fund

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

MyAvana, originally known as Madame You, specializes in personalized hair care solutions by integrating artificial intelligence with expert advice. The company offers a mobile application that provides users with a scientific analysis of their hair type and texture. Through this platform, users receive tailored recommendations for hair products and styling techniques that best suit their individual needs. By leveraging data-driven insights, MyAvana aims to empower women to make informed decisions regarding their hair care, enhancing their overall experience and satisfaction.

Chase Therapeutics is an early-stage specialty pharmaceutical company dedicated to developing innovative treatments for brain diseases. The company focuses on creating novel compounds that address both symptomatic relief and disease modification, aiming to enhance the quality of life for individuals affected by central nervous system disorders. Through its research and development efforts, Chase Therapeutics seeks to provide new therapeutic options that improve patient outcomes in the realm of brain health.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Chase Pharmaceuticals, established in 2007 and headquartered in Washington D.C., is a specialty pharmaceutical company dedicated to developing treatments for Alzheimer's disease and related neurodegenerative disorders. The company focuses on identifying and clinically developing promising drug candidates, with a particular emphasis on Alzheimer's disease, which currently lacks effective treatments. Chase Pharmaceuticals' lead product, CPC-252, is a transdermal formulation aimed at treating Alzheimer's disease and Parkinsonism dementia. The company operates as a subsidiary of Allergan plc, leveraging its expertise in neuroscience and drug development to advance novel compounds through clinical trials and towards global regulatory approval.

Satoris is a company focused on the development and commercialization of neurodiagnostic tests aimed at identifying neurological diseases such as Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy. The company is dedicated to creating tests that provide early, accurate, and clinically relevant diagnoses, which can lead to improved patient care and reduced healthcare costs. By prioritizing convenience and affordability, Satoris aims to enhance access to essential diagnostic services for patients facing these neurological conditions.